ExpreS2ion Biotech

In connection with the Q1 2026 report, we have updated our investment case. Q1 2026 has moved ExpreS2ion meaningfully forward and further derisked the investment case, with continued positive ES2B-C001 read-outs, a redesigned and strengthened Phase I programme, and a completed rights issue potentially securing the company's path to the end-2026 Phase I read-out.

Today, ExpreS2ion Biotechnologies' management presented the financial results for Q1 2026, provided further insights into the recent pipeline developments with focus on the breast cancer, malaria and Nipah candidates, and shared the latest updates on the completed rights issue and the partnering outlook for ES2B-C001.

ExpreS2ion is expected to release its Q1 2026 interim report on 28 May 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.

ExpreS2ion today announced an update to the Phase I program for ES2B-C001 alongside additional preliminary observations and study design changes. Anti-HER2 antibody responses have now been observed in 9 of 9 evaluable patients, up from 8 of 9 in March, with titres maintained at later follow-up.

New Phase Ia clinical data from the University of Oxford's BIO-002 study on Malaria further validates the Expres2ion platform